- Home
- DRDB vs CLLS Comparison
DRDB vs CLLS Comparison
Compare DRDB & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRDB
- CLLS
- Stock Information
- Founded
- DRDB 2024
- CLLS 1999
- Country
- DRDB United States
- CLLS France
- Employees
- DRDB N/A
- CLLS N/A
- Industry
- DRDB
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- DRDB
- CLLS Health Care
- Exchange
- DRDB Nasdaq
- CLLS Nasdaq
- Market Cap
- DRDB 315.3M
- CLLS 299.0M
- IPO Year
- DRDB 2024
- CLLS 2007
- Fundamental
- Price
- DRDB $10.29
- CLLS $2.85
- Analyst Decision
- DRDB
- CLLS Buy
- Analyst Count
- DRDB 0
- CLLS 1
- Target Price
- DRDB N/A
- CLLS $4.00
- AVG Volume (30 Days)
- DRDB 105.4K
- CLLS 199.3K
- Earning Date
- DRDB 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- DRDB N/A
- CLLS N/A
- EPS Growth
- DRDB N/A
- CLLS N/A
- EPS
- DRDB N/A
- CLLS N/A
- Revenue
- DRDB N/A
- CLLS $63,438,000.00
- Revenue This Year
- DRDB N/A
- CLLS N/A
- Revenue Next Year
- DRDB N/A
- CLLS $4.90
- P/E Ratio
- DRDB $587.82
- CLLS N/A
- Revenue Growth
- DRDB N/A
- CLLS 223.09
- 52 Week Low
- DRDB $9.87
- CLLS $1.10
- 52 Week High
- DRDB $10.43
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- DRDB N/A
- CLLS 59.27
- Support Level
- DRDB N/A
- CLLS $2.71
- Resistance Level
- DRDB N/A
- CLLS $3.08
- Average True Range (ATR)
- DRDB 0.00
- CLLS 0.20
- MACD
- DRDB 0.00
- CLLS -0.03
- Stochastic Oscillator
- DRDB 0.00
- CLLS 61.67
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.